Drugs that contain Lamivudine
1. Epivir patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US5905082 | VIIV HLTHCARE | Crystalline oxathiolane derivatives |
May, 2016
(7 years ago) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US5905082 | VIIV HLTHCARE | Crystalline oxathiolane derivatives |
May, 2016
(7 years ago) | |
|
US5905082 (Pediatric) | VIIV HLTHCARE | Crystalline oxathiolane derivatives |
Nov, 2016
(7 years ago) | |
| US6004968 | VIIV HLTHCARE | Pharmaceutical compositions containing lamivudine |
Mar, 2018
(6 years ago) | |
|
US6004968 (Pediatric) | VIIV HLTHCARE | Pharmaceutical compositions containing lamivudine |
Sep, 2018
(5 years ago) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Dosing Schedule(D-147) | Mar 23, 2018 |
Market Authorisation Date: 17 November, 1995
Treatment: NA
Dosage: TABLET;ORAL; SOLUTION;ORAL
More Information on Dosage
EPIVIR family patents
2. Epivir-hbv patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| USRE39155 | GLAXOSMITHKLINE | Use of 1,3-oxathiolane nucleoside analogues in the treatment of hepatitis B |
Jul, 2013
(10 years ago) | |
|
USRE39155 (Pediatric) | GLAXOSMITHKLINE | Use of 1,3-oxathiolane nucleoside analogues in the treatment of hepatitis B |
Jan, 2014
(10 years ago) | |
| US5905082 | GLAXOSMITHKLINE | Crystalline oxathiolane derivatives |
May, 2016
(7 years ago) | |
|
US5905082 (Pediatric) | GLAXOSMITHKLINE | Crystalline oxathiolane derivatives |
Nov, 2016
(7 years ago) | |
| US6004968 | GLAXOSMITHKLINE | Pharmaceutical compositions containing lamivudine |
Mar, 2018
(6 years ago) | |
|
US6004968 (Pediatric) | GLAXOSMITHKLINE | Pharmaceutical compositions containing lamivudine |
Sep, 2018
(5 years ago) | |
Market Authorisation Date: 08 December, 1998
Treatment: Treatment of hepatitis b infection
Dosage: SOLUTION;ORAL; TABLET;ORAL
More Information on Dosage
EPIVIR-HBV family patents